Longeveron LLC is a leading global regenerative medicine company developing innovative stem cell treatments that target chronic and life-threatening diseases. Through its exclusive licensing arrangements, Longeveron has been able to leverage existing data from Dr. Hare’s clinic research at the University of Miami. Longeveron now is at an advanced stage relative to when it was formed, and has multiple clinical trials underway.
CSO: Joshua M. Hare, MD, FACC, FAHA
COO: Suzanne Liv Page
Senior VP: Geoff Green
Formed in 2014, the company has rapidly expanded and is conducting clinical trials in several life-threatening indications considered to be large unmet medical needs:
- Hypoplastic Left Heart Syndrome (HLHS) in Newborns
- Aging Frailty
- Alzheimer’s Disease
- The Metabolic Syndrome
The Company’s most advanced investigational product candidate is Longeveron mesenchymal stem cells (LMSCs). LMSCs are derived from the bone marrow of healthy young adult donors.